Author

Anna Schuh

University of Oxford - Cited by 15,163

Biography

Anna Schuh is a well-known researcher working in Department of Internal Medicine, University Hospital Merkur and has extended valuable service for many years and has been a recipient of many awards and grants. Professor Schuh has participated as a principal or chief investigator in over 50 early and late phase clinical trials  in chronic lymphocytic leukaemia. 
Title
Cited by
Year
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ...Leukemia 36 (7), 1703-1719, 2022202
748
2022
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ...Leukemia 36 (7), 1720-1748, 2022202
610
2022
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
J Klintman, N Appleby, B Stamatopoulos, K Ridout, TA Eyre, P Robbe, ...Blood, The Journal of the American Society of Hematology 137 (20), 2800-2816, 2021202
47
2021
Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial
P Hillmen, A Pitchford, A Bloor, A Broom, M Young, B Kennedy, ...Blood 138, 642, 2021202
27
2021
TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes
M Eyres, S Lanfredini, H Xu, A Burns, A Blake, F Willenbrock, R Goldin, ...Gastroenterology 161 (2), 653-668. e16, 2021202
26
2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study
TA Eyre, A Schuh, WG Wierda, JR Brown, P Ghia, JM Pagel, RR Furman, ...The Lancet Haematology 8 (12), e912-e921, 2021202
23
2021
Clinical utility of whole-genome sequencing in precision oncology
R Rosenquist, E Cuppen, R Buettner, C Caldas, H Dreau, O Elemento, ...Seminars in Cancer Biology 84, 32-39, 2022202
23
2022
Signatures of TOP1 transcription-associated mutagenesis in cancer and germline
MAM Reijns, DA Parry, TC Williams, F Nadeu, RL Hindshaw, ...Nature 602 (7898), 623-631, 2022202
19
2022
Short and long-read genome sequencing methodologies for somatic variant detection; genomic analysis of a patient with diffuse large B-cell lymphoma
HE Roberts, M Lopopolo, AT Pagnamenta, E Sharma, D Parkes, L Lonie, ...Scientific Reports 11 (1), 6408, 2021202
16
2021
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
A Nasser, A Hussein, C Chamba, M Yonazi, R Mushi, A Schuh, L LuzzattoBlood advances 5 (5), 1403-1411, 2021202
16
2021
Management of cardiovascular complications of Bruton tyrosine kinase inhibitors
CPS Tang, GYH Lip, T McCormack, AR Lyon, P Hillmen, S Iyengar, ...British journal of haematology 196 (1), 70-78, 2022202
16
2022
Analytical demands to use whole-genome sequencing in precision oncology
M Meggendorfer, V Jobanputra, KO Wrzeszczynski, P Roepman, ...Seminars in Cancer Biology 84, 16-22, 2022202
14
2022
Guideline for the treatment of chronic lymphocytic leukaemia
R Walewska, N Parry-Jones, TA Eyre, G Follows, N Martinez-Calle, ...Br. J. Haematol 197, 544-557, 2022202
12
2022
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper
TA Eyre, JC Riches, PEM Patten, R Walewska, H Marr, G Follows, ...British journal of haematology 196 (4), 864-870, 2022202
10
2022
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
P Robbe, KE Ridout, DV Vavoulis, H Dréau, B Kinnersley, N Denny, ...Nature genetics 54 (11), 1675-168, 2022202
9
2022
Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology
V Jobanputra, KO Wrzeszczynski, R Buttner, C Caldas, E Cuppen, ...Seminars in Cancer Biology 4, 23-31, 2022202
8
2022
Implementation of whole-genome and transcriptome sequencing into clinical cancer care
E Cuppen, O Elemento, R Rosenquist, S Nikic, M IJzerman, ID Zaleski, ...JCO Precision Oncology 6, e2200245, 2022202
8
2022
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.
S de Botton, P Montesinos, A Schuh, C Papayannidis, P Vyas, AH Wei, ...Blood, blood. 2021014901-blood. 2021014901, 2022202
7
2022
Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry …
T Munir, A Pitchford, A Bloor, A Broom, M Young, B Kennedy, R Walewska, ...Blood 138, 2636, 2021202
7
2021
Combination of ibrutinib plus venetoclax with MRD-driven duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: Updated interim …
T Munir, A Pitchford, A Bloor, A Pettitt, PEM Patten, F Forconi, A Schuh, ...Blood 140 (Supplement 1), 231-233, 2022202
6
2022

Referred From: https://scholar.google.com/citations?user=gqJu8xYAAAAJ&hl=en

Cited by
Citations 15163
h-index 53
i10-index 136
Recommended Journals
Open Access Journals